News

June 21, 2019June 21, 2019

First Patient Dosed in Phase 3 Trial of Etrasimod for Moderate to Severe UC

News

The Phase 3 trial ELEVATE UC 52 evaluating Arena Pharmaceuticals’ investigational therapy etrasimod for patients with moderately to severely active ulcerative colitis has dosed its first patient. “We are pleased ... Read more

June 19, 2019June 19, 2019

Innovation Pharmaceuticals Signs Deal to Use Tablet Technology for Oral Brilacidin Treatment

News

Innovation Pharmaceuticals has signed an agreement to use OralogiK — an advanced tablet-coating technology patented by BDD Pharma — to develop tablets for targeted oral delivery of Brilacidin for ... Read more

June 17, 2019June 17, 2019

Nine-Month Results Show Continuing Efficacy of Abivax’s ABX464 in Extension Trial

News

Treatment with Abivax‘s ABX464 showed continuing effectiveness in ulcerative colitis patients, according to nine-month data of a maintenance clinical trial. The company is now recruiting people with moderate-to-severe ulcerative ... Read more

June 14, 2019June 14, 2019

IBD Mortality Rates Down in Recent Years, but Still Higher Than General Population, Study Reports

News

Although mortality rates associated with inflammatory bowel disease (IBD) have declined substantially over recent years, patients diagnosed with IBD as adults still have a higher risk of death than ... Read more

June 12, 2019June 12, 2019

25th Annual Gala for Crohn’s and Colitis Canada Raises $1.5M for IBD Care and Research

News

The Gala for Crohn’s and Colitis Canada recently raised nearly $1.5 million for research and patient programs, bringing the event’s 25-year total to $17.5 million and counting. About 900 ... Read more

June 7, 2019June 7, 2019

Mirikizumab Reduces Disease Activity in Active Crohn’s Disease, Phase 2 Trial Shows

News

Treatment with Elli Lilly’s mirikizumab led to a significant reduction in disease activity in moderate and severe Crohn’s disease patients after 12 weeks of treatment, findings from a Phase ... Read more

June 5, 2019June 5, 2019

Salix, Mitsubishi Tanabe Pharma to Develop and Commercialize MT-1303 for IBD

News

Mitsubishi Tanabe Pharma and Salix Pharmaceuticals have entered into an exclusive licensing agreement for MT-1303 (amiselimod), a therapeutic agent for autoimmune diseases including inflammatory bowel disease (IBD) and ulcerative ... Read more

June 3, 2019June 3, 2019

Rainin Foundation Calls for IBD Research Proposals for its Synergy Awards Program

News

The Kenneth Rainin Foundation is calling for innovative, collaborative research proposals on inflammatory bowel disease (IBD) for its Synergy Awards program. The foundation is accepting proposals from June 3 ... Read more

May 29, 2019May 29, 2019

First Prognostic Test for IBD Now Available for Patients in the UK and Ireland

News

PredictImmune‘s prognostic test for inflammatory bowel disease (IBD) is now available to clinicians and gastroenterologists in the U.K. and Ireland, the company announced. Developed in partnership with the University of ... Read more

May 22, 2019May 22, 2019

Helmsley Charitable Trust Grants $1.8 Million Toward Crohn’s Disease Research

News

The Leona M. and Harry B. Helmsley Charitable Trust has donated $1.8 million for the development of a gut-mimicking microdevice to help scientists better understand Crohn’s disease and develop new therapies. The ... Read more